- Company
- Samsung Biologics signed a contract with Lundbeck
- by Jul 22, 2020 06:16am
- Samsung Biologics announced on the 20th that it has signed a contract for biopharmaceutical contract worth &8361; 19.3 billion with global pharmaceutical company Lundbeck. The two companies signed their first contract on September 27, last year, and the size of the contract increased to &8361;19.3 billion ($15.99 million) under further
- Company
- Hanmi returns with salt-modified Champix generic
- by Kim, Jin-Gu Jul 22, 2020 06:15am
- Hanmi Pharmaceutical is trying the Champix (varenicline) generic market for the second time. Initially, the license on the Korean company’s generic Nocotine tablet was revoked, but it came back to the market with Nocotine S tablet with different substance. On July 20, Hanmi Pharmaceutical announced the launch of a varenicline generic No
- Company
- Will interferon have the potential to treat mild COVID-19?
- by Jul 22, 2020 06:15am
- Efforts have been made to continue to identify the potential for interferon preparations as a treatment for COVID-19. Interferon is one of the antiviral immune substances and increases the activity of innate immune cells (T cells, B cells, macrophages, etc.) to strengthen the human immune system. As the existing antiviral drugs such as K
- Company
- Ranitidine risk comes back as opportunity for Boryung
- by An, Kyung-Jin Jul 21, 2020 06:10am
- Korea’s Ministry of Food and Drug Safety (MFDS) has banned all sales of ranitidine drugs from Sept. 26 last year. After collecting and investigating ranitidine drugs, the ministry discovered unacceptable level of N-nitrosodimethylamine (NDMA). Also a month later, the ministry banned the sales of 13 nizatidine drugs with the same reason.
- Company
- Celltrion, commercially produce CT-P59 starting in September
- by An, Kyung-Jin Jul 21, 2020 06:10am
- Seo Jung-jin, Chairman at Celltrion Pharm, announced that the company will begin the production of COVID-19 antiviral antibody treatment that have entered the clinical stage. It is intended to quickly enter the commercialization stage by completing the verification of the adequacy and validity of production facilities early on. On the mor
- Company
- Complaint on how NHIS unveiled pricing negotiation guideline
- by Eo, Yun-Ho Jul 20, 2020 06:19am
- The pharmaceutical industry in Korea is complaining on how National Health Insurance Service (NHIS) announced the drug pricing negotiation guideline. According to the industry sources, Korean Research-based Pharmaceutical Industry Association (KRPIA) has recently submitted a statement to NHIS regarding the public opinion collection proced
- Company
- Prescription performance has been recovering since June
- by Chon, Seung-Hyun Jul 20, 2020 06:19am
- The overall outpatient prescription growth in the first half of this year has slowed. It remained at the same level as last year in the aftermath of COVID-19. However, prescription performance has been recovering since June, unlike April and May. As the fear of COVID-19 spread in the first quarter, patients received prescriptions all at on
- Company
- Rx of NOAC is recommended in COVID-19 epidemic
- by Eo, Yun-Ho Jul 17, 2020 05:55am
- The need for prescription of New Oral Anti-Coagulant (NOAC) is also emerging in COVID-19 outbreak. NOAC does not require periodic INR (International Normalized Ratio) monitoring, thus reducing visits to clinics unlike Warfarin. For this reason, NOAC is a good treatment option for patients who are unable to go to the hospital or need long-t
- Company
- Korean-made IMD Rosuzet and Zemimet prevail over COVID-19
- by An, Kyung-Jin Jul 17, 2020 05:55am
- Apparently a number of incrementally modified drugs (IMDs) developed with Korean-made technology excelled in the prescription drug market amid novel coronavirus (COVID-19) pandemic. A dyslipidemia combination drug Rosuzet and an antidiabetic combination drug Zemiglo recorded two-digit growth and settled on the top chart in the prescrip
- Company
- 2nd single-agent immunotherapy added for NSCLC first-line
- by Eo, Yun-Ho Jul 16, 2020 05:55am
- Another immunotherapy is expected to be added as a first-line treatment option in lung cancer. The pharmaceutical industry sources reported, Roche Korea has recently submitted an application to Korea’s Ministry of Food and Drug Safety (MFDS) to indicate programmed death-ligand 1 (PD-L1) inhibiting immunotherapy Tecentriq (atezolizumab)
